ArticleJournal of thoracic disease2026
Comparison of short-term changes in right ventricular function after catheter-directed thrombolysis-based therapy
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intermediate-risk pulmonary embolism (PE), defined by right ventricular (RV) dysfunction without hemodynamic instability, carries a significant risk of adverse outcomes. While anticoagulation is standard therapy, the optimal treatment strategy remains controversial. Catheter-directed thrombolysis (CDT) has emerged as a potential alternative to systemic thrombolysis, but its short-term efficacy and safety remain incompletely defined. This study aimed to compare the short-term improvement in RV function and the safety of CDT plus anticoagulation with anticoagulation alone in patients with acute intermediate-risk PE. Methods: Between March 2020 and February 2023, a total of 89 patients diagnosed with acute intermediate-risk PE were retrospectively identified, including 33 patients who received CDT plus anticoagulation (CDT group) and 56 patients who received anticoagulation alone. The primary outcome was the difference in the RV/left ventricular (LV) ratio at 1 week Results: The rate of improvement in the RV/LV ratio was significantly greater in the CDT group than in the anticoagulation group (34.0% Conclusions: Compared to anticoagulation alone, CDT seemed to obtain a rapid short-term improvement in RV function with no statistically significant increase in bleeding observed in this cohort, although larger studies are required to verify safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.